An Open-Label Phase 1/2 Study of the Safety and Efficacy of GCS-100 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2013
At a glance
- Drugs GCS 100 (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 25 Jan 2012 Status changed from suspended to discontinued.
- 20 May 2009 Status changed from recruiting to suspendedas reported by ClinicalTrials.gov.
- 20 Oct 2008 Actual start date changed from Feb 2008 to May 2008 as reported by ClinicalTrials.gov.